Phio Pharmaceuticals Corp. (PHIO)
NASDAQ: PHIO · Real-Time Price · USD
1.130
+0.030 (2.73%)
At close: May 13, 2026, 4:00 PM EDT
1.145
+0.015 (1.35%)
After-hours: May 13, 2026, 7:33 PM EDT
Phio Pharmaceuticals Employees
Phio Pharmaceuticals had 6 employees as of December 31, 2025. The number of employees increased by 1 or 20.00% compared to the previous year.
Employees
6
Change (1Y)
1
Growth (1Y)
20.00%
Revenue / Employee
n/a
Profits / Employee
-$1,822,000
Market Cap
13.13M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 6 | 1 | 20.00% | 6 | 0 |
| Dec 31, 2024 | 5 | -4 | -44.44% | 5 | 0 |
| Dec 31, 2023 | 9 | -1 | -10.00% | 8 | 1 |
| Dec 31, 2022 | 10 | -2 | -16.67% | 9 | 1 |
| Dec 31, 2021 | 12 | 2 | 20.00% | 12 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioLineRx | 24 |
| Kiora Pharmaceuticals | 13 |
| Cellectar Biosciences | 11 |
| Genenta Science | 9 |
| Intensity Therapeutics | 7 |
| Ernexa Therapeutics | 7 |
| Jupiter Neurosciences | 5 |
| Hoth Therapeutics | 3 |
PHIO News
- 6 days ago - Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update - Newsfile Corp
- 4 weeks ago - Phio Pharmaceuticals Transcript: Fireside chat - Transcripts
- 4 weeks ago - Phio Pharmaceuticals Transcript: Second Annual Centri Capital Conference - Transcripts
- 4 weeks ago - Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026 - Newsfile Corp
- 6 weeks ago - Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762 - Newsfile Corp
- 7 weeks ago - Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement - Newsfile Corp
- 2 months ago - Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office - Newsfile Corp
- 2 months ago - Phio Pharmaceuticals Transcript: Life Sciences Virtual Investor Forum - Transcripts